Pioneers in highlighting the key role of the vein of Marshall in atrial arrhythmias, Liryc's cardiologists anticipated the need for suitable catheters for ablation of this particular tissue.
Insensitive to ablation techniques used for the pulmonary veins, such as radiofrequency, this vestige of embryonic development must be chemically ablated by injecting alcohol at the entrance to the vein.
Building on their experience with existing tools and possible improvements, the clinicians Drs. Derval, Pambrun, Duchateau, Denis and Jaïs have conceptualized innovative catheters.
Once the design was done and the specifications for these new catheters defined and formalized in a patent application, it was essential to turn to a manufacturer of medical devices for creating the prototypes, which requires very specific skills.
Constructive discussions began with the Canadian company Agile MV, specialized in the manufacture of electrophysiology catheters for many years, who are known and recognized in the field. It was obvious to Agile MV, as well as to the clinical team, that everyone's skills would be the key to success. Agile MV was responsible for manufacturing the prototypes and the clinical team for their experimental validation.
As the partnership started in September 2019, the first prototypes are eagerly awaited for the start of 2020!
"he strength of this collaboration is the complementarity of skills! It's a in-win partnership!!" Jean-Luc Pageard, CEO Agile MV